136 related articles for article (PubMed ID: 33465277)
1. Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABA
Gurrell R; Whitlock M; Wei H; Shen Z; Ogden A
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):756-764. PubMed ID: 33465277
[TBL] [Abstract][Full Text] [Related]
2. Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.
Gurrell R; Gorman D; Whitlock M; Ogden A; Reynolds DS; DiVentura B; Abou-Khalil B; Gelfand M; Pollard J; Hogan RE; Krauss G; Sperling M; Vazquez B; Wechsler RT; Friedman D; Butt RP; French J
Neurology; 2019 Apr; 92(15):e1786-e1795. PubMed ID: 30877186
[TBL] [Abstract][Full Text] [Related]
3. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
4. Single- and Multiple-Dose Safety, Tolerability, and Pharmacokinetic Profiles of ASP8062: Results From 2 Phase 1 Studies.
Walzer M; Marek GJ; Wu R; Nagata M; Han D
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):297-306. PubMed ID: 31926000
[TBL] [Abstract][Full Text] [Related]
5. An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder.
Simen A; Whitlock M; Qiu R; Miceli J; Zumpano L; Du Metz M; Dua P; Binneman B
J Clin Psychopharmacol; 2019; 39(1):20-27. PubMed ID: 30531477
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
[TBL] [Abstract][Full Text] [Related]
7. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
8. A randomised, placebo-controlled clinical trial with the α2/3/5 subunit selective GABAA positive allosteric modulator PF-06372865 in patients with chronic low back pain.
Gurrell R; Dua P; Feng G; Sudworth M; Whitlock M; Reynolds DS; Butt RP
Pain; 2018 Sep; 159(9):1742-1751. PubMed ID: 29787472
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Whittaker A; Kragh ÅM; Hartleib-Geschwindner J; Albayaty M; Backlund A; Greasley PJ; Heijer M; Kjaer M; Forte P; Unwin R; Wernevik L; Ericsson H
Clin Transl Sci; 2020 Mar; 13(2):275-283. PubMed ID: 31584739
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
Othman AA; Haig G; Florian H; Locke C; Zhang J; Dutta S
Br J Clin Pharmacol; 2013 May; 75(5):1299-311. PubMed ID: 23016924
[TBL] [Abstract][Full Text] [Related]
11. Pronounced antiepileptic activity of the subtype-selective GABA
Duveau V; Buhl DL; Evrard A; Ruggiero C; Mandé-Niedergang B; Roucard C; Gurrell R
CNS Neurosci Ther; 2019 Feb; 25(2):255-260. PubMed ID: 30101518
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
13. SAGE-217, A Novel GABA
Hoffmann E; Nomikos GG; Kaul I; Raines S; Wald J; Bullock A; Sankoh AJ; Doherty J; Kanes SJ; Colquhoun H
Clin Pharmacokinet; 2020 Jan; 59(1):111-120. PubMed ID: 31338688
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.
Li GL; Winter H; Arends R; Jay GW; Le V; Young T; Huggins JP
Br J Clin Pharmacol; 2012 May; 73(5):706-16. PubMed ID: 22044402
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
18. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study.
Risinger R; Bhagwagar Z; Luo F; Cahir M; Miler L; Mendonza AE; Meyer JH; Zheng M; Hayes W
Psychopharmacology (Berl); 2014 Jun; 231(11):2299-310. PubMed ID: 24337079
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.
Zheng M; Appel L; Luo F; Lane R; Burt D; Risinger R; Antoni G; Cahir M; Keswani S; Hayes W; Bhagwagar Z
Psychopharmacology (Berl); 2015 Feb; 232(3):529-40. PubMed ID: 25116481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
